Email updates

Keep up to date with the latest news and content from Respiratory Research and BioMed Central.

Open Access Research

Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease

Renata Ferrari*, Suzana E Tanni, Laura MO Caram, Corina Corrêa, Camila R Corrêa and Irma Godoy

Author Affiliations

Faculdade de Medicina de Botucatu, Univ Estadual Paulista, Unesp, Disciplina de Pneumologia, Botucatu, São Paulo, Brazil

For all author emails, please log on.

Respiratory Research 2013, 14:24  doi:10.1186/1465-9921-14-24

Published: 20 February 2013

Abstract

Background

Past studies have shown that mean values of Interleukin-6 (IL-6) and C-reactive protein (CRP) do not change significantly in COPD patients over a one-year period. However, longer period follow-up studies are still lacking. Thus, the aim of this study is to evaluate plasma CRP and IL-6 concentration over three years in COPD patients and to test the association between these inflammatory mediators and disease outcome markers.

Methods

A cohort of 77 outpatients with stable COPD was evaluated at baseline, and 53 (mean FEV1, 56% predicted) were included in the prospective study. We evaluated Interleukin-6 (IL-6), C-reactive protein (CRP), six-minute walking distance (6MWD), and body mass index (BMI) at baseline and after three years. Plasma concentration of IL-6 was measured by high sensitivity ELISA, and CRP was obtained by high sensitivity particle-enhanced immunonephelometry.

Results

IL-6 increased significantly after 3 years compared to baseline measurements [0.8 (0.5-1.3) vs 2.4 (1.3-4.4) pg/ml; p < 0.001] and was associated with worse 6MWD performance. In the Cox regression, increased IL-6 at baseline was associated with mortality [Hazard Ratio (95% CI) = 2.68 (0.13, 1.84); p = 0.02]. CRP mean values did not change [5 (1.6-7.9) vs 4.7 (1.7-10) pg/L; p = 0.84], although eleven patients (21%) presented with changes >3 mg/L in CRP after 3 years.

Conclusions

The systemic inflammatory process, evaluated by IL-6, seems to be persistent, progressive and associated with mortality and worse physical performance in COPD patients.

Trial registration

No.:NCT00605540

Keywords:
Inflammation; Biomarkers; Exercise; Chronic Obstructive Pulmonary Disease